reports
Profound Medical Announces First Commercial BPH Patient Treatment Usin...
Profound Medical Announces First Commercial BPH Patient Treatment Using TULSA-PRO® with TULSA-AI® Volume Reduction TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, is pleased to announce that the first commercial benign prostatic hyperplasia (“BPH”) treatment utilizing the TULSA-PRO® system’s new TULSA-AI® Volume Reduction Module was successfully conducted yesterday by Naveen Kella, M.D.,...
Famed Former NFL Safety, Leonard Wheeler, Named Global Ambassador For ...
Famed Former NFL Safety, Leonard Wheeler, Named Global Ambassador For TULSA-PRO® TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, is pleased to announce that it has entered into a consulting agreement with , a former NFL player turned entrepreneur, author, corporate consultant, co-Executive Director of the , and more recently, national . This landmark partnership ushers in a dynamic ...
Profound Medical Corp: 3 directors
Three Directors at Profound Medical Corp bought 51,590 shares at between 4.139USD and 4.605USD. The significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors o...
Profound Medical Annual General and Special Meeting of Shareholders Vo...
Profound Medical Annual General and Special Meeting of Shareholders Voting Results TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders that was held today (the “Meeting”). A total of 20,587,011 common shares, representing 68.5% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company’s management information...
Profound Medical Announces First Quarter 2025 Financial Results
Profound Medical Announces First Quarter 2025 Financial Results TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the first quarter ended March 31, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP). Bu...
Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthc...
Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the 2025 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, May 6, 2025 at 1:30 p.m. Eastern Time at the Metro Toronto Convention Centre. The presentation will be ...
Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate M...
Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy – First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate cancer – – TULSA had no blood loss and no overnight stay, along with reduced post-procedure pain, and more rapid recovery to baseline activities and overall health – TORONTO, April 29, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device ...
Profound Medical to Release First Quarter 2025 Financial Results on Ma...
Profound Medical to Release First Quarter 2025 Financial Results on May 8 – Conference Call to Follow TORONTO, April 17, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Firs...
Profound Medical AUA 2025 Investor Event Agenda
Profound Medical AUA 2025 Investor Event Agenda TORONTO, April 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today additional details regarding its hybrid (in-person and virtual) investor event taking place on Monday, April 28, 2025, during the American Urological Association’s (“AUA”) Annual Meeting. The event will be held at the Waldorf Astoria in Las Vegas, NV. The agenda will commence at 3:30 p.m...
Save the Date: Profound Medical to Host Investor Event at AUA 2025
Save the Date: Profound Medical to Host Investor Event at AUA 2025 TORONTO, March 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will host a hybrid (in-person and virtual) investor event on Monday, April 28, 2025, during the American Urological Association’s (“AUA”) Annual Meeting in Las Vegas, NV, from 3:30 p.m. to 5:00 p.m. Pacific Time (6:30 p.m. to 8:00 p.m. Eastern Time). “The program will feature presenta...
Profound Medical Announces Fourth Quarter and Full Year 2024 Financial...
Profound Medical Announces Fourth Quarter and Full Year 2024 Financial Results TORONTO, March 06, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the fourth quarter and full year ended December 31, 2024. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting princ...
Profound Medical to Release Fourth Quarter and Full Year 2024 Financia...
Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss busin...
Update: Profound Medical’s Scheduled Presentation at the 43rd Annual J...
Update: Profound Medical’s Scheduled Presentation at the 43rd Annual J.P. Morgan Healthcare Conference Moved Up to 9:00am PT on January 16th TORONTO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that its scheduled presentation time at the 43rd Annual J.P. Morgan Healthcare Conference has been changed to 9:00 a.m. Pacific Time on Thursday, January 16, 2025. The presentation will be bro...
Profound Medical Announces Preliminary Unaudited Fourth Quarter and Fu...
Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues – Fourth quarter revenue growth estimated at 105% to 110% year-over-year – – Company to start reporting in accordance with U.S. GAAP and filing with the SEC on U.S. domestic forms – – Profound reminds investors that it is scheduled to present at JPM 2025 on January 16th at 11:15 a.m. PT – TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for th...
Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare ...
Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 11:15 a.m. Pacific Time in San Francisco, CA. The presentation will be broadcast live and archived on the...
Profound Medical Announces Closing of US$40.25 Million Underwritten Pu...
Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of common shares (the “Common Shares”) at a public offering price of US$7.50 per Common Share. The underwriters elected to exercise the over-allotment option in full, resulting in an aggregate of 5,366,705 Common Shares being issued today for aggregate gross proceeds, be...
Profound Medical Announces Pricing of US$35 Million Underwritten Publi...
Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares BASE SHELF PROSPECTUS IS ACCESSIBLE, AND FINAL PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced the pricing of an underwritten public offering (the “Offering”) of 4,666,700 common shares (the “Common Shares”) at a public offering price of US$7.50 per Common Share. The gross proceeds of the Offering to Profound, befor...
Profound Medical Announces Proposed Public Offering of Common Shares
Profound Medical Announces Proposed Public Offering of Common Shares BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced that it intends to offer and sell common shares (the “Common Shares”) in an underwritten public offering (the “Offering”). In addition, Profound expects to grant the underwriters of the Offering a 30-day option to purchase up to an additional 15% of the Com...
Profound Medical and Siemens Healthineers to Offer a Complete Solution...
Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy – Combines Profound’s TULSA-PRO® and Siemens Healthineers’ Magnetom Free.Max – – Supports the Modern Treatment Pathway that allows for more accurate and precise diagnosis, treatment, and follow-up – – Aligns well with CMS 2025 Final Rule establishing Urology APC Level 7 reimbursement for TULSA procedure at all 3 sites of service – TORONTO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops an...
Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assist...
Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant’ TULSA procedure’s unrivaled flexibility, real-world efficacy and ongoing CAPTAIN post-market study to be featured in the scientific programs at the upcoming RSNA and SUO meetings TORONTO, Nov. 26, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, is pleased to announce the unveiling of its third TULSA-AI® software module, UA Alignment Assistan...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.